The quandary over Antiviral Therapy for a COVID-19 Patient with Glucose-6- Phosphate Dehydrogenase Deficiency, Hypertension, and Resolved Hepatitis B Infection: A Case Report

Coronavirus disease (covid-19) pandemic has affected worldwide health care. given the possibility for coronavirus to prompt oxidative stress, masked glucose-6-phosphate dehydrogenase deficiency (g6pd) deficiency in the presence of the covid-19 viral infection may instigate hemolytic crisis and dangerous consequences in affected individuals. g6pd deficiency is an xlinked recessive disorder that affects some 400 million people worldwide, with a higher prevalence in africa, the mediterranean region, and asia. a dearth of studies and literature on available antivirals for managing covid-19 patients with g6pd deficiency brings the healthcare workers to a conundrum. here, we report an interesting symptomatic case of covid-19 patient with g6pd deficiency, hypertension, and resolved hepatitis b. antiviral therapy for covid-19 positive patients with g6pd deficiency should be individualized by considering the risk and benefit of treatment involved, recommending a multidisciplinary team approach.